Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares stood at 7.06 million during the last session, with the company’s beta value hitting 1.26. At the close of trading, the stock’s price was $2.40, to imply an increase of 9.59% or $0.21 in intraday trading. The LXRX share’s 52-week high remains $3.79, putting it -57.92% down since that peak but still an impressive 61.67% since price per share fell to its 52-week low of $0.92. The company has a valuation of $590.98M, with an average of 4.14 million shares in intraday trading volume over the past 10 days and average of 4.79 million shares over the past 3 months.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
After registering a 9.59% upside in the last session, Lexicon Pharmaceuticals Inc (LXRX) has traded red over the past five days. The stock hit a weekly high of 2.47, jumping 9.59% in its intraday price action. The 5-day price performance for the stock is -0.41%, and -8.05% over 30 days. With these gigs, the year-to-date price performance is 56.86%. Short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw shorts transact 21.35 million shares and set a 3.31 days time to cover.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Looking at statistics comparing Lexicon Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Lexicon Pharmaceuticals Inc (LXRX) shares are 98.35% up over the last 6 months, with its year-to-date growth rate lower than industry average at 10.13% against 13.00%. Revenue is forecast to shrink -17.60% this quarter before jumping 18.20% for the next one. The rating firms project that company’s revenue will grow 2,043.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $1.37 million. Meanwhile, for the quarter ending Jun 2024, a total of 3 analyst(s) estimate revenue growth to $2.97 million.
LXRX Dividends
Lexicon Pharmaceuticals Inc has its next earnings report out between April 30 and May 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Lexicon Pharmaceuticals Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders hold 1.66% of total outstanding shares, with institutional holders owning 82.29% of the shares at 83.68% float percentage. In total, 82.29% institutions holds shares in the company, led by Artal Group S.A.. As of Dec 30, 2023, the company held over 117.55 million shares (or 47.74% of shares), all amounting to roughly $282.13 million.
The next major institution holding the largest number of shares is BVF Inc. with 24.44 million shares, or about 9.92% of shares outstanding. As of the market price on Dec 30, 2023, these shares were worth $58.65 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Lexicon Pharmaceuticals Inc (LXRX) shares. Going by data provided on Dec 30, 2023, Vanguard Total Stock Market Index Fund holds roughly 3.7 million shares. This is just over 1.50% of the total shares, with a market valuation of $8.89 million. Data from the same date shows that the other fund manager holds a little less at 2.33 million, or 0.94% of the shares, all valued at about 5.58 million.
